Ask AI
TROP2 TIGIT Lung Cancer

CE / CME

Expert Analysis: Clinical Advances Journal Club on Emerging TROP-2 and TIGIT Therapies in Lung Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

European Learners: 1.00 EBAC® CE Credit

Released: January 22, 2026

Expiration: July 21, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this module, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest and ongoing data for anti–TROP-2 antibody–drug conjugates (ADCs) and anti-TIGIT agents in non-small-cell lung cancer (NSCLC) and their prospects in the treatment paradigm, as well as the data for these agents in small-cell lung cancer (SCLC).

Please note that the slide thumbnails in this activity link to a PowerPoint slideset that may be downloaded by clicking on any of the thumbnails within the activity.

Decera Clinical Education plans to measure the education impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this education activity, please take a moment to answer the following questions.

How many people with lung cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

A patient with metastatic NSCLC and an EGFR exon 19 deletion experiences progression after first-line treatment with osimertinib and platinum-based chemotherapy. Which of the following treatment options would you recommend for this patient based on available evidence and current approved indications?

Which of the following anti-TIGIT therapies has shown promising efficacy in combination with zimberelimab for first-line treatment of PD-L1-high (PD-L1 tumor proportion score [TPS] ≥50%) metastatic NSCLC?

Based on eligibility criteria for the phase II VELOCITY-Lung Substudy-01 evaluating combinations of zimberelimab with domvanalimab, SG, and etrumadenant, which of the following patients with advanced lung cancer could be considered for enrollment on this trial?

Which of the following patients with SCLC would be a candidate for enrollment on the phase III EVOKE-SCLC-04 trial comparing SG with the current standard of care?